What are the preferred combination trastuzumab regimens for the treatment of HER2/neu-positive metastatic breast cancer?

Updated: Apr 23, 2020
  • Author: Joseph A Sparano, MD; Chief Editor: John V Kiluk, MD, FACS  more...
  • Print


Regimens are as follows:

  • PCH: Carboplatin AUC 6 IV on day 1 plus  paclitaxel 175 mg/m2 IV on day 1 every 3 wk plus  trastuzumab (Herceptin) or

  • Weekly PCH: Paclitaxel 80 mg/m2 IV on days 1, 8, and 15 plus  carboplatin AUC 2 IV on days 1,8, and 15 every 4 wk plus trastuzumab

  • Pertuzumab/trastuzumab/docetaxel: pertuzumab 840 mg IV plus  trastuzumab 8 mg/kg IV plus  docetaxel 75 mg/m2 IV on day 1, then  pertuzumab 420 mg plus  trastuzumab 6 mg/kg plus  docetaxel 75 mg/m2 q3 wk (may increase docetaxel to 100 mg/m2 if initial dose well tolerated) [41]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!